Shinichi Toyooka

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 76%
3. Lung Transplantation 56%
4. Lung 50%
5. ErbB Receptors 41%
6. Methylation 39%
7. Neoplasms 34%
8. Mutation 32%
9. Chemoradiotherapy 30%
10. Living Donors 27%
11. Gefitinib 24%
12. Adenocarcinoma of Lung 24%
13. erbB-1 Genes 22%
14. Malignant Mesothelioma 22%
15. Cell Line 22%
16. Radiofrequency Ablation 21%
17. Survival 21%
18. Genes 15%
19. Breast Neoplasms 14%
20. Neoplasm Metastasis 14%
21. Protein-Tyrosine Kinases 13%
22. human ERBB2 protein 13%
23. Therapeutics 13%
24. Transplants 11%
25. Japan 11%
26. Docetaxel 10%
27. Tomography 10%
28. Cisplatin 9%
29. Polymerase Chain Reaction 9%
30. Small Cell Lung Carcinoma 8%
31. Recurrence 8%
32. Thorax 8%
33. Smokers 8%
34. DNA Methylation 7%
35. Survival Rate 7%
36. Afatinib 7%
37. Tumor Suppressor Genes 7%
38. Exons 7%
39. Adjuvant Chemotherapy 7%
40. MicroRNAs 7%
41. Epigenomics 7%
42. Smoking 6%
43. Lymph Nodes 6%
44. Tissue Donors 6%
45. human DAB2 protein 6%
46. Adenocarcinoma 6%
47. Drug Therapy 6%
48. Allografts 6%
49. Databases 6%
50. Needle Biopsy 5%